Key result
Tie-2 glycation by advanced glycation end products inhibits Ang-1 signaling activation and Ang-1-induced angiogenesis in vitro and ex vivo.
Why the study?
Impairment of Ang-1/Tie-2 signaling is thought to play a critical role in diabetic complications, but the underlying mechanisms remain unclear.
Tie-2 glycation by advanced glycation end products inhibits Ang-1 signaling and angiogenesis, providing a potential mechanism for angiogenesis failure in diabetic ischemic diseases.
May link AGE-mediated Tie-2 glycation to angiogenesis failure in diabetic ischemia; hypothesis-generating and requires human validation before clinical consideration.
The impairment of the angiopoietin-1 (Ang-1)/Tie-2 signaling pathway has been thought to play a critical role in diabetic complications. However, the underlying mechanisms remain unclear. The present study aims to investigate the effects of Tie-2 glycation on Ang-1 signaling activation and Ang-1-induced angiogenesis. We identified that Tie-2 was modified by advanced glycation end products (AGEs) in aortae derived from high fat diet (HFD)-fed mice and in methylglyoxal (MGO)-treated human umbilical vein endothelial cells (HUVECs). MGO-induced Tie-2 glycation significantly inhibited Ang-1-evoked Tie-2 and Akt phosphorylation and Ang-1-regulated endothelial cell migration and tube formation, whereas the blockade of AGE formation by aminoguanidine remarkably rescued Ang-1 signaling activation and Ang-1-induced angiogenesis in vitro. Furthermore, MGO treatment markedly increased AGE cross-linking of Tie-2 in cultured aortae ex vivo and MGO-induced Tie-2 glycation also significantly decreased Ang-1-induced vessel outgrow from aortic rings. Collectively, these data suggest that Tie-2 may be modified by AGEs in diabetes mellitus and that Tie-2 glycation inhibits Ang-1 signaling activation and Ang-1-induced angiogenesis. This may provide a novel mechanism for Ang-1/Tie-2 signal dysfunction and angiogenesis failure in diabetic ischaemic diseases.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2022) studied Diabetic complications (preclinical model). Methylglyoxal (MGO)-induced Tie-2 glycation vs. Control / Aminoguanidine blockade was evaluated on Ang-1 signaling activation and Ang-1-induced angiogenesis. Tie-2 glycation by advanced glycation end products inhibits Ang-1 signaling activation and Ang-1-induced angiogenesis in vitro and ex vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: